Abbott Laboratories (ABT) 43.40 $ABT
Research and Markets: China POCT Market 2014-2018: Abbott Laboratories, Bayer HealthCare, F. Hoffmann-La Roche & LifeScan Dominates the Market
Business Wire - 58 mins ago
Research and Markets (http://www.researchandmarkets.com/research/r3shd9/poct_market_in) has announced the addition of the "POCT Market in China 2014-2018" report to their offering.
China POCT Market 2014-2018: Abbott Laboratories, Bayer HealthCare, F. Hoffmann-La Roche & LifeScan Dominates the Market
M2 - 1 hr 18 mins ago
Research and Markets (http://www.researchandmarkets.com/research/gch85q/poct_market_in) has announced the addition of the "POCT Market in China 2014-2018" report to their offering. The POCT market in China to grow at a CAGR of 20.69% over the period 2013-2018 POCT, also called near-patient testing, is performed outside a clinical laboratory. It helps in making fast clinical decisions, and hence in administrating appropriate treatments and medication. POCT is gaining popularity due to the increasing incidence and prevalence of lifestyle diseases such as diabetes, heart disease, and obesity. It is generally cost-effective and user-friendly. POCT devices are standardized to minimize errors during the diagnosis of patients. POCT plays a major role in improving patients' quality of life. The expanding economy of China is one of the major trends witnessed in this market. The Government of China is making efforts to improve healthcare infrastructures, which has benefited the POCT market. According to the report, one of the major drivers in the market is the increase in innovations in technology to provide efficient and inexpensive devices to diagnose and treat diseases. Advances in technology and innovations in the Healthcare industry have resulted in the development of equipment with technology that is customized as per the needs of the patient. Further, the report states that one of the major challenges in the market is the advances in technology. The entry of new technology in the market forces the frequent elimination of the POCT products of the large vendors. To calculate the market size, the report considers the revenue generated through the following applications of POCT: - Blood glucose testing - Cholesterol testing - Infectious disease testing - Blood gas testing - Cardiac biomarkers testing - Pregnancy testing - Others (such as cancer biomarker, electrolyte analyzers, blood coagulation testing, tumor marker, and urinalysis testing) Key Vendors - Abbott Laboratories - Bayer HealthCare - F. Hoffmann-La Roche - LifeScan Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Market Segmentation by Technology - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/gc..._market_in
Novo Nordisk Reveals Fresh Data on Xultophy for Diabetes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 5:20PM CDT
Novo Nordisk (NVO) announced data from new analyses of the phase IIIa DUAL I and DUAL II studies on Xultophy.
Novartis' (NVS) Data on Anti-Cancer Drug LBH589 Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 3:45PM CDT
Novartis (NVS) announced that positive data on its pipeline candidate, LBH589 (panobinostat), was published in The Lancet Oncology.
Research and Markets: Global PCR Technologies Global Market 2014-2020
Business Wire - Mon Sep 22, 3:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rb5tts/pcr_technologies) has announced the addition of the "PCR Technologies Global market - Forecast to 2020" report to their offering.
Global PCR Technologies Global Market 2014-2020
M2 - Mon Sep 22, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kvrrv/pcr_technologies) has announced the addition of the "PCR Technologies Global market - Forecast to 2020" report to their offering. Some of the key players in the PCR market are Abbott Laboratories, Affymetrix, inc., Takara bio, Agilent Technologies, Beckman Coulter Inc., Quanta biosciences, Bio-Rad, Becton, Dickinson and Co., GE Healthcare, Sigma-Aldrich Corp., and Roche. Polymerase chain reaction (PCR) is a gene amplification technique that amplifies a single or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. PCR plays a crucial role in understanding the genetic diseases and is also used in the characterization and detection of infectious disease organisms in diseases like Lyme disease, AIDS, middle ear infection and tuberculosis. PCR is an indispensable technique in Biotechnology, drug discovery and clinical diagnostics and it's key applications include DNA sequencing, Forensic science, Genotyping, Bioinformatics, gene expression, genetic mapping and DNA cloning. PCR products market includes Reagents, consumables, instruments, software and services. Some of the key techniques available in market are Standard/basic PCR, Real-time/Q-PCR, Digital PCR (dPCR), Reverse transcriptase PCR, Assembly PCR, Inverse PCR, Nested PCR, Multiplex PCR, Hot start PCR and touchdown PCR Among the various techniques, Q-PCR appears to be the fastest growing in PCR market followed by Reverse-Transcription PCR (RT-PCR) and Assembly. Based on the classification by products/tools, PCR Reagents is expected to be fastest growing PCR market followed by PCR Consumables and Machines. The global PCR market is projected to grow at a healthy rate. North America would account for the largest market share followed by Europe and Asia-pacific. Increasing number of patients suffering from Infectious diseases, Cancers and positive investments in gene therapy and human genome project are further driving the growth of the PCR market. Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 PCR Market by Types 5 PCR Market by Application 6 PCR Market by Technology 7 Regional Market Analysis 8 Company Developments 9 Major Company Profiles - Abbott Laboratories - Becton, Dickinson And Co. - Bio-Rad - Ge Healthcare - Kapa Biosystems - Maxim Biotech - Promega Corp. - Quanta Biosciences Inc. - Roche - Sigma-Aldrich Corp. - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/4k...chnologies
Global In-Vitro Diagnostics (POC/Rapid Diagnostics) Market 2014-2020
M2 - Mon Sep 22, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kjf5z9/in_vitro) has announced the addition of the "In Vitro Diagnostics (POC/Rapid diagnostics) Global market - Forecast to 2020" report to their offering. The focus of this research report description was on various levels of analysis, industry, market shares, value chain, PESTEL analysis and company profiles which together comprise and augment about competitive landscape, emerging and high growth segments of in vitro diagnostic (molecular diagnostics & point of care testing), emerging technologies. In vitro diagnostics are tests that diagnose and prevent diseases, conditions or infections. IVD tests are performed outside body in an artificial environment on samples such as blood, urine, tissue isolated from human body. IVD is classified into 3 types namely: clinical laboratory testing, near-patient testing, self-testing. IVD market is segmented by-techniques (including immunoassays, point of care, molecular diagnostics, hematology, coagulation, microbiology, clinical techniques, microbiology), product-type (including instruments, reagents, services, data management systems), usability (including disposable, reusable), applications (including diabetes, oncology, cardiology, HIV/AIDS, autoimmune disease, nephrology, drug testing), -end-user (including hospitals, laboratories, academics) and geography (globally). Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Global Ivd Market, By Technique 5. Global Ivd Market, By Products 6. Global Ivd Market, By Application 7. Global Ivd Market, By End-Users 8. Regional Market Analysis 9. Company Developments 10. Major Player Profiles - Abbott Laboratories, Inc. - Becton, Dickinson and company - Biomerieux - Bio-Rad Laboratories, Inc - Danaher Corporation - Johnson and Johnson - Roche Diagnostics - Siemens Healthcare - Sysmex Corporation - Thermo Fischer Scientific, Inc For more information visit http://www.researchandmarkets.com/research/kjf5z9/in_vitro
Dividend Aristocrats: Time to Buy AbbVie Inc Stock?
George Budwell, The Motley Fool - Motley Fool - Fri Sep 19, 11:32AM CDT
Dividend stocks are a powerful force within a well-balanced portfolio because they can dramatically increase the rate of compounding interest through dividend reinvestment plans. Not all dividend stocks are great investment vehicles, however. For...
Jim Cramer's 'Mad Money' Recap: Hooray for the Federal Reserve
at The Street - Wed Sep 17, 7:08PM CDT
Now that the Fed has done the right thing on monetary policy, investors should stop worrying and start thinking about how to make more money, Cramer says.
Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.12% Rise
Comtex SmarTrend(R) - Wed Sep 17, 4:27PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $42.76 to a high of $43.57. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $42.97 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 4:05PM CDT
Abbott Labs (ABT) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb.
Global Hemoglobin A1c Testing Devices (Laboratory Testing Devices & POC testing Devices) Market Analysis 2013-2019
M2 - Wed Sep 17, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjh9n8/hemoglobin_a1c) has announced the addition of the "Hemoglobin A1c Testing Devices Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. 'Testing the levels of glycated hemoglobin provides an assurance to the healthcare practitioner about the patient's blood glucose level. This test can be used for diagnosis and monitoring of hemoglobin A1c levels in diabetic patients. Since A1C test reflects the average amount of glucose for the past 2 to 3 months, it is opined to be more reliable than conventional blood glucose test. Physicians are increasingly prescribing HbA1c test to their patients which will lead to an increase in the test volume. Moreover, rising diabetes incidence rate is a major driver for the HbA1c testing market. With growing awareness about prevention and management of diabetes, the demand for HbA1c testing devices will rise rapidly especially in the Asia-Pacific, Latin America, MiddleEast and African regions. Moreover, advent of these devices for the diagnosis of diabetes will further bolster the demand for these devices in future. For instance, approval for the COBAS INTEGRA 800 Tina-quant HbA1cDx assay, in 2013and Abbott's ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test approved in 2014 for the diagnosis of diabetes were the major steps in the hemoglobin A1c testing industry. With this diagnostic tools, physicians can combat the rising incidence of diabetes with timely and appropriate actions in identifying and managing diabetes. Based on the end-use, the global hemoglobin A1c testing devices market is categorized into two segments namely laboratory testing and point-of-care (POC) testing devices. Laboratory testing devices held the majority share of the market in 2012, while the global market for point-of-care testing devices is expected to grow at a faster paceduring the forecast period. Based on technologies, the hemoglobin A1c testing devices market is further categorized into five segments, namely, ion-exchange HPLC, immunoassay, boronate affinity chromatography, direct enzymatic assay and others. The boronate affinity chromatography market will be growing at a faster pace during the forecast period as this technology has no interference from hemoglobin variants and is also used in both laboratory as well as point-of-care testing. Healthcare practitioners are recommending the use of devices which offer least variant interference and this would elevate the demand for boronate affinity chromatography in HbA1c testing. The global hemoglobin A1c testing devices market is categorized into the following segments: Hemoglobin A1cTesting Devices Market, by End-use - Laboratory Testing Devices - Point-of-Care (POC)Testing Devices Hemoglobin A1cTesting Devices Market, by Technology - Ion-Exchange High Performance Liquid Chromatography (HPLC) - Immunoassay - Boronate Affinity Chromatography - Direct Enzymatic Assay - Others (Micro-Optical Detection Method and Capillary Electrophoresis) Key Topics Covered: - Introduction - Executive Summary - Global Hemoglobin A1c Testing Devices Market Overview - Global Hemoglobin A1c Testing Devices Market, by End-Use - Global Hemoglobin A1c Testing Devices Market, by Technology - Global Hemoglobin A1c Testing Devices Market, by Geography - Recommendations - Company Profiles - ARKRAY, Inc. - Abbott Laboratories - Alere, Inc. - Bio-Rad Laboratories, Inc. - Chek Diagnostics (Polymer Technology Systems, Inc.) - Danaher Corporation (Beckman Coulter) - EKF Diagnostics Holdings plc - F. Hoffmann-La Roche Ltd. - Menarini Group - Sebia - Siemens Healthcare - Tosoh Corporation - Trinity Biotech plc For more information visit http://www.researchandmarkets.com/research/bj...globin_a1c
Global Molecular Diagnostics (Infectious Disease Testing, Blood Screening, Cancer Screening) 2014-2020 - Strategic Business Report
M2 - Wed Sep 17, 2:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w9ktnt/molecular) has announced the addition of the "Molecular Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Molecular Diagnostics in US$ Thousands by the following Applications: Infectious Disease Testing, Blood Screening, Cancer Screening, and Other Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 165 companies including many key and niche players such as: - Abbott Laboratories - Becton, Dickinson and Company - bioM?rieux SA - Cepheid - CytoCore Inc. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Medical Diagnostics Market A Review 3. Molecular Diagnostics Industry An Overview 4. An Insight Into Applications Of Molecular Diagnostics 5. Competitive Dynamics In The Molecular Diagnostics Market 6. Product & Technology Overview 7. Product Approvals/Introductions 8. Recent Industry Activity 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 165 (including Divisions/Subsidiaries 179) - The United States (113) - Canada (3) - Japan (1) - Europe (50) - France (7) - Germany (11) - The United Kingdom (12) - Italy (2) - Spain (1) - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (11) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/w9ktnt/molecular
Research and Markets: Global Companion Diagnostics Market 2014-2019: Roche Diagnostics, Abbott Laboratories, Agilent Technologies, QIAGEN N.V. & Thermo Fisher Scientific Dominate with 86% Market Share
Business Wire - Tue Sep 16, 10:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rcg9gj/companion) has announced the addition of the "Companion Diagnostics Market byTechnology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering.
Abbott Laboratories Has Returned 9.9% Since SmarTrend Recommendation (ABT)
Comtex SmarTrend(R) - Tue Sep 16, 9:18AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 5 months, Abbott Laboratories has returned 9.89% as of today's recent price of $42.58.
Global Companion Diagnostics Market 2014-2019: Roche Diagnostics, Abbott Laboratories, Agilent Technologies, QIAGEN N.V. & Thermo Fisher Scientific Dominate with 86% Market Share
M2 - Tue Sep 16, 9:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8dnfmg/companion) has announced the addition of the "Companion Diagnostics Market byTechnology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering. The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3,136.9 million in 2014, growing at a CAGR of 22.7% during the forecast period (2014 to 2019). This market is segmented by technology, application, and end user. Technologies are further subsegmented into immunohistochemistry, in situ hybridization (fluoroscent ISH and chromogenic ISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS)-based tests. The application market is further subsegmented into breast cancer, lung cancer, melanoma cancer, and colorectal cancer. The end users are majorly segmented into pharmaceutical companies and reference laboratories. Among technologies, the polymerase chain reaction (PCR)-based test accounted for the largest share of 65.5% in 2013. The growth of companion diagnostic in the other application segments (neurological diseases, infectious diseases, ovarian cancer, and leukemia) is expected to grow at a CAGR of 30.3%; whereas, on the basis of end user, reference laboratories is expected to grow at the fastest rate in the market. The major application driving the global companion diagnostics market is the adoption of companion diagnostic tests in oncology for various indications and for target therapies. Currently, breast, lung colorectal, and melanoma are the major types of cancer for which FDA approved companion diagnostics are available. In addition, encouragement by regulatory bodies and acceptance of tests by end users are the prominent factors for growth of market. Notable restraining factors include varied reimbursement procedures in different regions and usage of non-validated tests for identification of biomarkers. However, advanced technologies such as next-generation sequencing and growth of companion diagnostic in prostate cancer, leukemia, ovarian cancer, Alzheimer's disease, and Parkinson's disease are likely to augment the global companion diagnostic market in the future. In 2013, Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), QIAGEN N.V. (Netherlands), and Thermo Fisher Scientific Inc. (U.S.) together accounted for a share of 86% of the global companion diagnostics market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Global Companion Diagnostics Market, By Applications 8 Global Companion Diagnostics Market, By Technology 9 Market, By End User 10 Global Companion Diagnostics Market, By Geography 11 Competitive Landscape 12 Company Profiles - Abbott Laboratories, Inc. - Agilent Technologies, Inc. - Biogenex Laboratories - Biom?rieux - Danaher Corporation - Ge Healthcare - Myriad Genetics, Inc. - Qiagen N.V. - Roche Diagnostics - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/8dnfmg/companion
Abbott Included In Top 10 Best Companies by Working Mother Magazine
PR Newswire - Tue Sep 16, 8:11AM CDT
Abbott's (NYSE: ABT) long-held commitment to supporting working mothers and their families was acknowledged today by Working Mother magazine. The healthcare company was named among the Top 10 companies in Working Mother's 100 Best Companies list, which commends companies for establishing a corporate culture that supports working moms. This marks the fourteenth consecutive year that Abbott has been included in the esteemed ranking.
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:20PM CDT
Abbott Laboratories (ABT) announced positive one-year results from the randomized, controlled trial ABSORB II, on its drug-eluting coronary bioresorbable vascular scaffold (BVS) Absorb.
Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device
PR Newswire - Mon Sep 15, 8:30AM CDT
Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. Absorb is the world's first drug eluting BVS and functions like a metallic stent by opening up blocked blood vessels in the heart and restoring blood flow. However, unlike a metallic stent, Absorb completely dissolves over time after doing its job. ABSORB IV is designed to enroll approximately 3,000 people with coronary artery disease, mostly in the United States.
Research and Markets: China POCT Market 2014-2018: Abbott Laboratories, Bayer HealthCare, F. Hoffmann-La Roche & LifeScan Dominates the Market
Business Wire - 58 mins ago
Research and Markets (http://www.researchandmarkets.com/research/r3shd9/poct_market_in) has announced the addition of the "POCT Market in China 2014-2018" report to their offering.
China POCT Market 2014-2018: Abbott Laboratories, Bayer HealthCare, F. Hoffmann-La Roche & LifeScan Dominates the Market
M2 - 1 hr 18 mins ago
Research and Markets (http://www.researchandmarkets.com/research/gch85q/poct_market_in) has announced the addition of the "POCT Market in China 2014-2018" report to their offering. The POCT market in China to grow at a CAGR of 20.69% over the period 2013-2018 POCT, also called near-patient testing, is performed outside a clinical laboratory. It helps in making fast clinical decisions, and hence in administrating appropriate treatments and medication. POCT is gaining popularity due to the increasing incidence and prevalence of lifestyle diseases such as diabetes, heart disease, and obesity. It is generally cost-effective and user-friendly. POCT devices are standardized to minimize errors during the diagnosis of patients. POCT plays a major role in improving patients' quality of life. The expanding economy of China is one of the major trends witnessed in this market. The Government of China is making efforts to improve healthcare infrastructures, which has benefited the POCT market. According to the report, one of the major drivers in the market is the increase in innovations in technology to provide efficient and inexpensive devices to diagnose and treat diseases. Advances in technology and innovations in the Healthcare industry have resulted in the development of equipment with technology that is customized as per the needs of the patient. Further, the report states that one of the major challenges in the market is the advances in technology. The entry of new technology in the market forces the frequent elimination of the POCT products of the large vendors. To calculate the market size, the report considers the revenue generated through the following applications of POCT: - Blood glucose testing - Cholesterol testing - Infectious disease testing - Blood gas testing - Cardiac biomarkers testing - Pregnancy testing - Others (such as cancer biomarker, electrolyte analyzers, blood coagulation testing, tumor marker, and urinalysis testing) Key Vendors - Abbott Laboratories - Bayer HealthCare - F. Hoffmann-La Roche - LifeScan Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Market Segmentation by Technology - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/gc..._market_in
Novo Nordisk Reveals Fresh Data on Xultophy for Diabetes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 5:20PM CDT
Novo Nordisk (NVO) announced data from new analyses of the phase IIIa DUAL I and DUAL II studies on Xultophy.
Novartis' (NVS) Data on Anti-Cancer Drug LBH589 Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 3:45PM CDT
Novartis (NVS) announced that positive data on its pipeline candidate, LBH589 (panobinostat), was published in The Lancet Oncology.
Research and Markets: Global PCR Technologies Global Market 2014-2020
Business Wire - Mon Sep 22, 3:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rb5tts/pcr_technologies) has announced the addition of the "PCR Technologies Global market - Forecast to 2020" report to their offering.
Global PCR Technologies Global Market 2014-2020
M2 - Mon Sep 22, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kvrrv/pcr_technologies) has announced the addition of the "PCR Technologies Global market - Forecast to 2020" report to their offering. Some of the key players in the PCR market are Abbott Laboratories, Affymetrix, inc., Takara bio, Agilent Technologies, Beckman Coulter Inc., Quanta biosciences, Bio-Rad, Becton, Dickinson and Co., GE Healthcare, Sigma-Aldrich Corp., and Roche. Polymerase chain reaction (PCR) is a gene amplification technique that amplifies a single or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. PCR plays a crucial role in understanding the genetic diseases and is also used in the characterization and detection of infectious disease organisms in diseases like Lyme disease, AIDS, middle ear infection and tuberculosis. PCR is an indispensable technique in Biotechnology, drug discovery and clinical diagnostics and it's key applications include DNA sequencing, Forensic science, Genotyping, Bioinformatics, gene expression, genetic mapping and DNA cloning. PCR products market includes Reagents, consumables, instruments, software and services. Some of the key techniques available in market are Standard/basic PCR, Real-time/Q-PCR, Digital PCR (dPCR), Reverse transcriptase PCR, Assembly PCR, Inverse PCR, Nested PCR, Multiplex PCR, Hot start PCR and touchdown PCR Among the various techniques, Q-PCR appears to be the fastest growing in PCR market followed by Reverse-Transcription PCR (RT-PCR) and Assembly. Based on the classification by products/tools, PCR Reagents is expected to be fastest growing PCR market followed by PCR Consumables and Machines. The global PCR market is projected to grow at a healthy rate. North America would account for the largest market share followed by Europe and Asia-pacific. Increasing number of patients suffering from Infectious diseases, Cancers and positive investments in gene therapy and human genome project are further driving the growth of the PCR market. Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 PCR Market by Types 5 PCR Market by Application 6 PCR Market by Technology 7 Regional Market Analysis 8 Company Developments 9 Major Company Profiles - Abbott Laboratories - Becton, Dickinson And Co. - Bio-Rad - Ge Healthcare - Kapa Biosystems - Maxim Biotech - Promega Corp. - Quanta Biosciences Inc. - Roche - Sigma-Aldrich Corp. - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/4k...chnologies
Global In-Vitro Diagnostics (POC/Rapid Diagnostics) Market 2014-2020
M2 - Mon Sep 22, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kjf5z9/in_vitro) has announced the addition of the "In Vitro Diagnostics (POC/Rapid diagnostics) Global market - Forecast to 2020" report to their offering. The focus of this research report description was on various levels of analysis, industry, market shares, value chain, PESTEL analysis and company profiles which together comprise and augment about competitive landscape, emerging and high growth segments of in vitro diagnostic (molecular diagnostics & point of care testing), emerging technologies. In vitro diagnostics are tests that diagnose and prevent diseases, conditions or infections. IVD tests are performed outside body in an artificial environment on samples such as blood, urine, tissue isolated from human body. IVD is classified into 3 types namely: clinical laboratory testing, near-patient testing, self-testing. IVD market is segmented by-techniques (including immunoassays, point of care, molecular diagnostics, hematology, coagulation, microbiology, clinical techniques, microbiology), product-type (including instruments, reagents, services, data management systems), usability (including disposable, reusable), applications (including diabetes, oncology, cardiology, HIV/AIDS, autoimmune disease, nephrology, drug testing), -end-user (including hospitals, laboratories, academics) and geography (globally). Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Global Ivd Market, By Technique 5. Global Ivd Market, By Products 6. Global Ivd Market, By Application 7. Global Ivd Market, By End-Users 8. Regional Market Analysis 9. Company Developments 10. Major Player Profiles - Abbott Laboratories, Inc. - Becton, Dickinson and company - Biomerieux - Bio-Rad Laboratories, Inc - Danaher Corporation - Johnson and Johnson - Roche Diagnostics - Siemens Healthcare - Sysmex Corporation - Thermo Fischer Scientific, Inc For more information visit http://www.researchandmarkets.com/research/kjf5z9/in_vitro
Dividend Aristocrats: Time to Buy AbbVie Inc Stock?
George Budwell, The Motley Fool - Motley Fool - Fri Sep 19, 11:32AM CDT
Dividend stocks are a powerful force within a well-balanced portfolio because they can dramatically increase the rate of compounding interest through dividend reinvestment plans. Not all dividend stocks are great investment vehicles, however. For...
Jim Cramer's 'Mad Money' Recap: Hooray for the Federal Reserve
at The Street - Wed Sep 17, 7:08PM CDT
Now that the Fed has done the right thing on monetary policy, investors should stop worrying and start thinking about how to make more money, Cramer says.
Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.12% Rise
Comtex SmarTrend(R) - Wed Sep 17, 4:27PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $42.76 to a high of $43.57. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $42.97 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 4:05PM CDT
Abbott Labs (ABT) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb.
Global Hemoglobin A1c Testing Devices (Laboratory Testing Devices & POC testing Devices) Market Analysis 2013-2019
M2 - Wed Sep 17, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjh9n8/hemoglobin_a1c) has announced the addition of the "Hemoglobin A1c Testing Devices Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. 'Testing the levels of glycated hemoglobin provides an assurance to the healthcare practitioner about the patient's blood glucose level. This test can be used for diagnosis and monitoring of hemoglobin A1c levels in diabetic patients. Since A1C test reflects the average amount of glucose for the past 2 to 3 months, it is opined to be more reliable than conventional blood glucose test. Physicians are increasingly prescribing HbA1c test to their patients which will lead to an increase in the test volume. Moreover, rising diabetes incidence rate is a major driver for the HbA1c testing market. With growing awareness about prevention and management of diabetes, the demand for HbA1c testing devices will rise rapidly especially in the Asia-Pacific, Latin America, MiddleEast and African regions. Moreover, advent of these devices for the diagnosis of diabetes will further bolster the demand for these devices in future. For instance, approval for the COBAS INTEGRA 800 Tina-quant HbA1cDx assay, in 2013and Abbott's ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test approved in 2014 for the diagnosis of diabetes were the major steps in the hemoglobin A1c testing industry. With this diagnostic tools, physicians can combat the rising incidence of diabetes with timely and appropriate actions in identifying and managing diabetes. Based on the end-use, the global hemoglobin A1c testing devices market is categorized into two segments namely laboratory testing and point-of-care (POC) testing devices. Laboratory testing devices held the majority share of the market in 2012, while the global market for point-of-care testing devices is expected to grow at a faster paceduring the forecast period. Based on technologies, the hemoglobin A1c testing devices market is further categorized into five segments, namely, ion-exchange HPLC, immunoassay, boronate affinity chromatography, direct enzymatic assay and others. The boronate affinity chromatography market will be growing at a faster pace during the forecast period as this technology has no interference from hemoglobin variants and is also used in both laboratory as well as point-of-care testing. Healthcare practitioners are recommending the use of devices which offer least variant interference and this would elevate the demand for boronate affinity chromatography in HbA1c testing. The global hemoglobin A1c testing devices market is categorized into the following segments: Hemoglobin A1cTesting Devices Market, by End-use - Laboratory Testing Devices - Point-of-Care (POC)Testing Devices Hemoglobin A1cTesting Devices Market, by Technology - Ion-Exchange High Performance Liquid Chromatography (HPLC) - Immunoassay - Boronate Affinity Chromatography - Direct Enzymatic Assay - Others (Micro-Optical Detection Method and Capillary Electrophoresis) Key Topics Covered: - Introduction - Executive Summary - Global Hemoglobin A1c Testing Devices Market Overview - Global Hemoglobin A1c Testing Devices Market, by End-Use - Global Hemoglobin A1c Testing Devices Market, by Technology - Global Hemoglobin A1c Testing Devices Market, by Geography - Recommendations - Company Profiles - ARKRAY, Inc. - Abbott Laboratories - Alere, Inc. - Bio-Rad Laboratories, Inc. - Chek Diagnostics (Polymer Technology Systems, Inc.) - Danaher Corporation (Beckman Coulter) - EKF Diagnostics Holdings plc - F. Hoffmann-La Roche Ltd. - Menarini Group - Sebia - Siemens Healthcare - Tosoh Corporation - Trinity Biotech plc For more information visit http://www.researchandmarkets.com/research/bj...globin_a1c
Global Molecular Diagnostics (Infectious Disease Testing, Blood Screening, Cancer Screening) 2014-2020 - Strategic Business Report
M2 - Wed Sep 17, 2:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w9ktnt/molecular) has announced the addition of the "Molecular Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Molecular Diagnostics in US$ Thousands by the following Applications: Infectious Disease Testing, Blood Screening, Cancer Screening, and Other Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 165 companies including many key and niche players such as: - Abbott Laboratories - Becton, Dickinson and Company - bioM?rieux SA - Cepheid - CytoCore Inc. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Medical Diagnostics Market A Review 3. Molecular Diagnostics Industry An Overview 4. An Insight Into Applications Of Molecular Diagnostics 5. Competitive Dynamics In The Molecular Diagnostics Market 6. Product & Technology Overview 7. Product Approvals/Introductions 8. Recent Industry Activity 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 165 (including Divisions/Subsidiaries 179) - The United States (113) - Canada (3) - Japan (1) - Europe (50) - France (7) - Germany (11) - The United Kingdom (12) - Italy (2) - Spain (1) - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (11) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/w9ktnt/molecular
Research and Markets: Global Companion Diagnostics Market 2014-2019: Roche Diagnostics, Abbott Laboratories, Agilent Technologies, QIAGEN N.V. & Thermo Fisher Scientific Dominate with 86% Market Share
Business Wire - Tue Sep 16, 10:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rcg9gj/companion) has announced the addition of the "Companion Diagnostics Market byTechnology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering.
Abbott Laboratories Has Returned 9.9% Since SmarTrend Recommendation (ABT)
Comtex SmarTrend(R) - Tue Sep 16, 9:18AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 5 months, Abbott Laboratories has returned 9.89% as of today's recent price of $42.58.
Global Companion Diagnostics Market 2014-2019: Roche Diagnostics, Abbott Laboratories, Agilent Technologies, QIAGEN N.V. & Thermo Fisher Scientific Dominate with 86% Market Share
M2 - Tue Sep 16, 9:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8dnfmg/companion) has announced the addition of the "Companion Diagnostics Market byTechnology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering. The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3,136.9 million in 2014, growing at a CAGR of 22.7% during the forecast period (2014 to 2019). This market is segmented by technology, application, and end user. Technologies are further subsegmented into immunohistochemistry, in situ hybridization (fluoroscent ISH and chromogenic ISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS)-based tests. The application market is further subsegmented into breast cancer, lung cancer, melanoma cancer, and colorectal cancer. The end users are majorly segmented into pharmaceutical companies and reference laboratories. Among technologies, the polymerase chain reaction (PCR)-based test accounted for the largest share of 65.5% in 2013. The growth of companion diagnostic in the other application segments (neurological diseases, infectious diseases, ovarian cancer, and leukemia) is expected to grow at a CAGR of 30.3%; whereas, on the basis of end user, reference laboratories is expected to grow at the fastest rate in the market. The major application driving the global companion diagnostics market is the adoption of companion diagnostic tests in oncology for various indications and for target therapies. Currently, breast, lung colorectal, and melanoma are the major types of cancer for which FDA approved companion diagnostics are available. In addition, encouragement by regulatory bodies and acceptance of tests by end users are the prominent factors for growth of market. Notable restraining factors include varied reimbursement procedures in different regions and usage of non-validated tests for identification of biomarkers. However, advanced technologies such as next-generation sequencing and growth of companion diagnostic in prostate cancer, leukemia, ovarian cancer, Alzheimer's disease, and Parkinson's disease are likely to augment the global companion diagnostic market in the future. In 2013, Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), QIAGEN N.V. (Netherlands), and Thermo Fisher Scientific Inc. (U.S.) together accounted for a share of 86% of the global companion diagnostics market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Global Companion Diagnostics Market, By Applications 8 Global Companion Diagnostics Market, By Technology 9 Market, By End User 10 Global Companion Diagnostics Market, By Geography 11 Competitive Landscape 12 Company Profiles - Abbott Laboratories, Inc. - Agilent Technologies, Inc. - Biogenex Laboratories - Biom?rieux - Danaher Corporation - Ge Healthcare - Myriad Genetics, Inc. - Qiagen N.V. - Roche Diagnostics - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/8dnfmg/companion
Abbott Included In Top 10 Best Companies by Working Mother Magazine
PR Newswire - Tue Sep 16, 8:11AM CDT
Abbott's (NYSE: ABT) long-held commitment to supporting working mothers and their families was acknowledged today by Working Mother magazine. The healthcare company was named among the Top 10 companies in Working Mother's 100 Best Companies list, which commends companies for establishing a corporate culture that supports working moms. This marks the fourteenth consecutive year that Abbott has been included in the esteemed ranking.
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:20PM CDT
Abbott Laboratories (ABT) announced positive one-year results from the randomized, controlled trial ABSORB II, on its drug-eluting coronary bioresorbable vascular scaffold (BVS) Absorb.
Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device
PR Newswire - Mon Sep 15, 8:30AM CDT
Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. Absorb is the world's first drug eluting BVS and functions like a metallic stent by opening up blocked blood vessels in the heart and restoring blood flow. However, unlike a metallic stent, Absorb completely dissolves over time after doing its job. ABSORB IV is designed to enroll approximately 3,000 people with coronary artery disease, mostly in the United States.
